Navigation Links
Cephalon Reports Another Strong Quarter
Date:10/28/2008

Record Sales of $490 Million, Up 14 Percent over Third Quarter 2007

Company Raises Full Year 2008 Sales and Earnings Guidance Introduces 2009 Adjusted Net Income Guidance, Up 27 Percent over 2008

FRAZER, Pa., Oct. 28 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today reported third quarter 2008 sales of $489.7 million, compared to sales of $428.7 million for the third quarter of 2007, and at the high end of the company's guidance of $480 - $490 million. Net income for the quarter was $112.0 million and basic income per common share was $1.64. Excluding amortization expense and certain other items, adjusted net income was $92.9 million and basic adjusted income per common share for the quarter was $1.36, compared to $1.08 for the same period in 2007, exceeding the company's guidance of $1.25 to $1.35.

Central nervous system (CNS) franchise sales were $273.7 million during the quarter, a 19 percent increase compared to the same period last year. The Pain franchise sales were $117.2 million compared to $121.8 million in the third quarter of 2007. AMRIX(R) (cyclobenzaprine hydrochloride extended- release capsules) sales increased 20 percent over the second quarter 2008. Oncology franchise sales were $52.4 million, an increase of 131 percent versus 2007. Sales of TREANDA(R) (bendamustine hydrochloride) for Injection were $24.6 million for the quarter, an increase of 71 percent over the second quarter of 2008.

"More and more patients are benefiting from the novel therapies that we offer. This has resulted in record sales, and adjusted earnings that exceeded the high end of our guidance. These solid results, and our confidence in our current product portfolio, enabled us to raise our guidance for the remainder of this year and issue adjusted net income guidance for 2009 that exceeds today's First Call consensus," said Frank Baldino, Jr., Ph.D., Chairman and CEO. "Despite troubled economic conditions around the world, our
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
10. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
11. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced ... three large odour control systems for waste water treatment plants ... are consistent with the market resurgence in North ... CEO. "After a difficult period of restraint in our core ... sales growth. Our lower cost structure, technology improvements and supply ...
(Date:9/2/2014)... September 2, 2014 Culot brings ... and lab management services  BioData, producer of ... pleased to announce the appointment of Louis Culot ... served as VP Marketing and Business Development at BioDiscovery ... and clinical applications. Previously, Culot worked for ...
(Date:9/1/2014)... The global oligonucleotide synthesis market is ... $1,070.7 million in 2014, growing at a CAGR ... oligonucleotide synthesis market is categorized on the basis ... geography. The synthesized oligonucleotides segment is expected to ... synthesis market during the forecast period, owing to ...
(Date:8/31/2014)... Available spectra is similar for ... and cultivation of a wide range of plants. ... with proven patented and pending wide spectrum technology. ... in critical applications in contrast to growth spectra ... customers have a large variety of differently sized ...
Breaking Biology Technology:Louis Culot Appointed as BioData's CEO 29.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 29.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 39.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 49.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 5
... Anadys Pharmaceuticals,Inc. (Nasdaq: ANDS ), a biopharmaceutical ... medicines in the areas of hepatitis C and,oncology, ... the first,quarter ended March 31, 2008., "We ... programs,during the first quarter," said Steve Worland, Ph.D., ...
... SAN CARLOS, Calif., April 30 Nektar,Therapeutics (Nasdaq: ... quarter ended March 31, 2008 on Wednesday, May 7, ... president and chief,executive officer, will host a conference call ... access the press release and a live audio-only Webcast ...
... Dohlsten, M.D., Ph.D., To Succeed As President, Wyeth Research ... WYE ),today announced that Robert R. Ruffolo, Jr., ... Vice President, Wyeth, later this,year. He will be succeeded ... Wyeth in November 2000 and has been responsible for,all ...
Cached Biology Technology:Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights 2Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights 3Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights 4Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights 5Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights 6Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights 7Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights 8Nektar to Announce Q1 2008 Financial Results on Wednesday, May 7, 2008, After Close of U.S.-Based Financial Markets 2Wyeth Research Head Robert R. Ruffolo, Jr., Ph.D., Announces Retirement 2
(Date:9/2/2014)... enough to prevent Type 2 diabetes, don,t get your hopes ... The FASEB Journal , suggests that you ... This study compared genetically identical twins-one heavier and one leaner-and ... including those related to Type 2 diabetes, were found in ... that the onset of this type of diabetes is largely ...
(Date:9/2/2014)... the price of your integrity? Tell the truth; everyone has ... at some point, we,ll lie if the benefit is great ... in which we make that decision. , The result ... . , "We prefer to be honest, even if ... and a postdoctoral associate at the Virginia Tech Carilion ...
(Date:9/2/2014)... Tithonian Konservat-Lagersttte of lithographic limestone is well known ... fossils from that area (for example, Archaeopteryx). Now, ... insects in the French equivalent of these outcrops ... the oldest known water treader. , Despite the ... fewer fossils have been obtained from the Late ...
Breaking Biology News(10 mins):What you eat and not just the number of calories, is a significant factor in diabetes risk 2Scientists find possible neurobiological basis for tradeoff between honesty, self-interest 2Scientists find possible neurobiological basis for tradeoff between honesty, self-interest 3Scientists find possible neurobiological basis for tradeoff between honesty, self-interest 4Exceptionally well preserved insect fossils from the Rhône Valley 2
... trauma, say from a sabertooth tiger attack, meant immediate death ... to survive severe injury caused by a car crash, gunshot ... does not know what to do when it survives an ... evolution. Nearly one third of the time, mechanisms in place ...
... that the ability of plants to defend themselves by accumulating ... some insects, and that such adaptation potentially echoes in the ... evolve to deal with high levels of the toxic element. ... and colleagues there and at the University of California, Berkeley, ...
... and proteins that explain how animals discern bitter from sweet, ... mutant fruit flies prefer eating sugar over sugar laced with ... that a single protein missing from the fly-equivalent of our ... the caffeine as if it were not there. , "No, ...
Cached Biology News:PNAS study reveals why organs fail following massive trauma 2PNAS study reveals why organs fail following massive trauma 3PNAS study reveals why organs fail following massive trauma 4PNAS study reveals why organs fail following massive trauma 5New moth variety disarms plants guarded by selenium 2Psst! Coffee drinkers: Fruit flies have something to tell you about caffeine 2Psst! Coffee drinkers: Fruit flies have something to tell you about caffeine 3
Extra Large bottle for hybridization 300 x 70mm...
Request Info...
... Microtube Rotor is TWO ROTORS in ONE! ... You can spin both 1.5 - ... polypropylene rotor design provides excellent chemical resistance ... rotors are fully compatible with common decontamination ...
... Wellpro 384, compatible ... automated liquid handling system ... quickly and accurately prepares ... dilutions. The Wellpro ...
Biology Products: